Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356846 | 0.87 | TSHR (0.40) | CYP1A2CYP3A4TSHRMAPK1DRD3 | |
| SCHEMBL30006601 | 0.84 | CYP3A4 (0.38) | CYP1A2CYP3A4TSHRMAPK1DRD3 | |
| SCHEMBL21218742 | 0.81 | CYP1A2 (0.43) | CYP1A2CYP3A4TSHRMAPK1DRD3 | |
| SCHEMBL1793576 | 0.80 | CYP1A2 (0.52) | CYP1A2CYP3A4TSHRMAPK1 | |
| SCHEMBL21218762 | 0.79 | APEX1 (0.38) | CYP1A2TSHR | |
| SCHEMBL19624709 | 0.79 | ALDH1A1 (0.33) | CYP1A2TSHRDRD3PDE3BPDE3A | |
| SCHEMBL120101 | 0.75 | TSHR (0.39) | CYP3A4TSHRMAPK1 | |
| SCHEMBL23249000 | 0.75 | CYP3A4 (0.32) | CYP1A2CYP3A4TSHRMAPK1DRD3 | |
| SCHEMBL658795 | 0.75 | ACHE (0.43) | CYP1A2CYP3A4MAPK1DRD3ESR2 | |
| SCHEMBL14138399 | 0.75 | ALDH1A1 (0.52) | CYP1A2CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724418-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-08 | — | — | US | disclosed |
| US-9318706-B2 | Laminated structure, method for producing same, and electronic element comprising same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20160081997-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-24 | — | — | US | disclosed |
| US-9227935-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICAL N.V. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20150320741-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| US-9107946-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-18 | — | — | US | disclosed |
| US-20150087629-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | disclosed |
| US-8946228-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-02-03 | — | — | US | disclosed |
| US-20110177312-A1 | LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| CN-1067994-C | Bisresorcinyltriazines | CIBA GEIGY AG (CH) | 2001-07-04 | — | — | CN | disclosed |
| US-5686233-A | PHOTOGRAPHIC FILM STABILIZER | CIBA-GEIGY CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| CN-1132747-A | Bisresorcinyltriazines | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177312-A1 | LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME | EPCAM, ITGA1, ITGB1 | CYP1A2 3022/4885CYP3A4 1671/4885TSHR 4526/4885 |
| US-20150320741-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | CYP1A2 644/4885CYP3A4 567/4885TSHR 1007/4885 |
| US-20150087629-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, NAT1, SOAT1 | CYP1A2 233/4885CYP3A4 740/4885TSHR 2514/4885 |
| US-20160081997-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, SOAT1 | CYP1A2 191/4885CYP3A4 726/4885TSHR 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.